Novartis Licenses Anti-PD1 Antibody Tislelizumab from BeiGene in US$2.2 B Deal
By Neha Madhwani & Michelle Liu
Pharma Deals Review: Vol 2021 Issue 2 (Table of Contents)
Published: 8 Feb-2021
DOI: 10.3833/pdr.v2021.i2.2591 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In another move to strengthen its immuno-oncology pipeline, Novartis has agreed to partner with BeiGene to develop and commercialise a PD-1 inhibitor, tislelizumab...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS